The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure

Journal of Ocular Pharmacology and Therapeutics

Volumn 20, Issue 4, 2004, Pages 321-327

  Kurtz, Shimon ^a,b   Shemesh, Gabi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; LATANOPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EYE BURNING; FEMALE; FOLLOW UP; FOREIGN BODY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OCULAR PRURITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION;

ADULT; AGED; ANALYSIS OF VARIANCE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PATIENT COMPLIANCE; PROSTAGLANDINS F, SYNTHETIC; PRURITUS; STATISTICS, NONPARAMETRIC;

EID: 4243061716     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/1080768041725353     Document Type: Article

References (11)

1. Alm, A., and Stjernschantz, J. The Scandinavian Study Group. Effects of intraocular pressure and side effects of 0.005% latanoprost applied once-daily, evening or morning: A comparison with timolol. Ophthalmology 102:1743-1752, 1995.
2. Linden, C., and Alm, A. Prostaglandin analogs in the treatment of glaucoma. Drugs Aging 14:387-398, 1999.
3. Data on file, Pharmacia & Upjohn; Kalamazoo, M., Sanchez, J.G. The Spanish Latanoprost Study Group. A 3-month comparison of latanoprost monotherapy to dorzolamide as adjunctive therapy to timolol in patients inadequately controlled on a topical beta-blocker. Presented at: The European Society of Ophthalmology (SOE); June 1999; Stockholm, Sweden.
4. Emmerich, K-Hon. A comparison of latanoprost monotherapy to dorzolamide combined with timolol in glaucoma and ocular hypertension patients. Graefes. Arch. Clin. Exp. Ophthalmol. 238:3-7, 2000.
5. Bucci, M.G. The Italian Latanprost Study Group. Intraocular pressure-lowering effect of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: A randomized, observer-masked, multicenter study in patients with open-angle glaucoma. J. Glaucoma 8:24-30, 1999.
6. Data on file, Pharmacia & Upjohn; Kalamazoo, M., Hedman, K., Alm, A. Long-term effect of latanoprost on intraocular pressure. Presented at the International Congress of Ophthalmology (ICO); June 1998; Amsterdam, the Netherlands.
7. Brubaker, R., Schoff, E., Nau, C., Carpenter, S.P., Chen, K., and Vandenburgh, A.M. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol. 131:19-24, 2001.
8. Camras, C. The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology 103:138-147, 1996.
9. Advanced Glaucoma Intervention Study, II. Visual field test scoring and reliability. Ophthalmology 101:1445-1455, 1994.
10. Camras, C. The U.S. Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 103:138-147, 1996.
11. Gandolfi, S.A., Vecchi, M. Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans. Invest. Ophthalmol. Vis. Sci. 37:684-688, 1996.